Back to News
Market Impact: 0.15

ETF Fundamental Report for IWM

IWMNDAQ
Company FundamentalsAnalyst InsightsHealthcare & BiotechMarket Technicals & Flows
ETF Fundamental Report for IWM

The Validea ETF fundamental report indicates that the iShares Russell 2000 ETF (IWM) is a Mid-Cap Value ETF with its largest sector allocation in Services and industry allocation in Biotechnology & Drugs. The ETF exhibits a value factor score of 56, momentum score of 30, quality score of 8, and low volatility score of 14, suggesting a moderate tilt towards value investing with relatively low quality and volatility characteristics.

Analysis

The Validea fundamental report for iShares Russell 2000 ETF (IWM) identifies it as a Mid-Cap Value ETF, with its largest sector exposure in Services and its most significant industry concentration in Biotechnology & Drugs. The ETF's factor analysis reveals a moderate Value score of 56 out of 99, which aligns with its stated investment style. However, its exposure to other key factors is notably weak: the Momentum score is low at 30, and more critically, the Quality score is exceptionally low at 8, accompanied by a Low Volatility score of 14. These latter scores indicate that the underlying holdings generally lack strong financial health, stable earnings, or characteristics associated with low price fluctuation, suggesting a risk profile that may be higher than what some investors might associate with a typical 'value' mandate. The significant presence of the Biotechnology & Drugs industry could be a contributing factor to these lower quality and higher volatility metrics.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.00

Ticker Sentiment

IWM0.00
NDAQ0.00

Key Decisions for Investors

  • Investors should carefully weigh IWM's moderate value characteristic (score of 56) against its significantly low quality (8) and low 'low volatility' (14) scores, which point to a portfolio of potentially less stable companies and higher price fluctuation.
  • The ETF's low momentum score of 30 suggests its constituents have not demonstrated strong recent price performance, making it potentially less attractive for momentum-focused investment strategies.
  • The notable concentration in the Services sector, specifically within Biotechnology & Drugs, warrants thorough due diligence as this industry's inherent volatility may contribute to IWM's overall low quality and higher volatility profile, which may not align with all risk appetites.